Pacific Hepatitis C Network (PHCN) offers current, locally relevant information (i.e. public coverage of hepatitis C treatment; clinical trails ongoing; local clinics and resources) through our hepctip.ca website. PHCN provides some phone support to those who reach via the website to provide additional information about accessing treatment. PHCN also offers a webinar based on the Hep C TIP website as well as tailored to specific communities and audiences. As well, PHCN works to inform government and other key stakeholders about the lived experience of patients and the impacts of health policy (and social determinants of health) on people living with an at-risk for hepatitis C. We are currently working with partners to establish a phone-based HCV Peer Navigation system that provides detailed, one-one assistance to find and connect with services, programs and clinics available in any given region of the province.
PHCN Programming Approaches
Accessible, Useful and Accurate The information and education we provide about hep C topics and issues is: accessible (easy to find and read, for instance); of interest to and good use for audiences; clear, accurate and up-to-date.
Community as Expert Skill and capacity building brings cutting-edge hepatitis C information/knowledge together with the expertise of communities.
PHCN Advocacy Approaches
Overarching Policy issues, such as how hep C treatment drugs are listed with BC Pharmacare.
Specific Policy and practice, such as how clinics handle addiction in patients needing hep C treatment.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close